“In this study, we have demonstrated for the first time in a placebo-controlled trial that cannabinoid treatment has the potential to decrease disruptive behaviors associated with ASD, with acceptable tolerability.”
House and Senate lawmakers have approved legislation, House Bill 324, to regulate the production and dispensing of low-THC oil extracts to qualified patients. Republican Gov. Brian Kemp has stated that he intends to sign the bill into law.
Regulators at the US Food and Drug Administration today granted market approval for Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), for the explicit treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.
A three judge panel for the Ninth Circuit Court of Appeals has denied a petition filed by the Hemp Industries Association challenging the DEA’s authority to establish a new administrative drug code specifically for marijuana extracts. Petitioners say that will appeal the ruling.
Oral CBD administration is associated with reduced blood pressure in healthy volunteers, according to clinical trial data published online in the Journal of Clinical Investigation.
Minnesota House and Senate lawmakers, along with Democrat Gov. Mark Dayton, agreed late last week to legislation that seeks to provide access to limited preparations of cannabis to qualified patients. Unlike other state medical cannabis programs, the Minnesota plan does not permit qualified patients to possess or obtain whole-plant cannabis. Instead, the forthcoming law mandates that state-licensed distribution centers provide oils, pills, and/or extracts prepared from the plant.
While some media outlets are reporting that the passage of these measures are akin to ‘approving medical marijuana,’ such claims are far from accurate.
[Editor’s note: This post is excerpted from this week’s forthcoming NORML weekly media advisory. To…